Aytu Biopharma (AYTU) Receivables - Net (2015 - 2026)

Aytu Biopharma (AYTU) has 12 years of Receivables - Net data on file, last reported at $24.5 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $24.5 million, down 31.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.5 million (down 31.64% YoY), and the FY2025 annual result was $31.2 million, up 22.91% from the prior year.
• Receivables - Net eased to $24.5 million in Q1 2026 per AYTU's latest filing, from $30.9 million in the prior quarter.
• Over five years, Receivables - Net peaked at $35.8 million in Q1 2025 and troughed at $23.2 million in Q3 2024.
• A 5-year average of $28.8 million and a median of $29.4 million in 2023 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2025 and 2026: Receivables - Net jumped 43.46% in 2025, then tumbled 31.64% in 2026.
• A 5-year view of Receivables - Net shows it stood at $25.5 million in 2022, then gained by 15.08% to $29.4 million in 2023, then fell by 13.6% to $25.4 million in 2024, then advanced by 21.73% to $30.9 million in 2025, then decreased by 20.81% to $24.5 million in 2026.
• Business Quant data shows AYTU's Receivables - Net at $24.5 million in Q1 2026, $30.9 million in Q4 2025, and $33.2 million in Q3 2025.